Shares of pharmaceutical company


(NOVN) - Get Report

were up about 14% for the week after the

Food and Drug Administration

expanded the approved uses of one of the company's products. The


said the transdermal drug delivery system developer could market the dime-sized estrogen patch Vivelle-Dot for the prevention of postmenopausal osteoporosis. Previously, the patch had only been approved for the treatment of menopausal symptoms. Noven said it will add a new 0.025 milligram a day strength patch to be used for the osteoporosis treatment.